UM LAPs - UG1 Grant

项目总结 密歇根大学(UM)，包括其综合癌症中心(UMCCC)和 医学院院系，要求将此UG1奖作为NCI国家临床试验 网络领先学术参与网站(NCTN LAPS-UG1)。我们将此机会视为 这是我们机构大型癌症研究工作的重要组成部分。我们将继续致力于 对多机构合作对癌症进展至关重要的概念 治疗。我们作为LAPS站点的目标是使重要的科学、领导、管理 以及患者数据对NCTN研究和改进癌症治疗的努力的贡献。这个 NCTN过程涉及开发和进行有目的的临床试验，采用 统一的毒性和反应标准、患者数据收集和结果报告。NCTN 群体研究是组合情态的复杂概念和 跨学科治疗和辅助治疗都可以得到适当的评估。NCTN临床 研究还提供了一个更好的理解之间的重要关系 以其他方式无法获得的预后因素、治疗和患者结果。

PROJECT SUMMARY The University of Michigan (UM), inclusive of its Comprehensive Cancer Center (UMCCC) and Medical School Departments, requests this UG1 award as an NCI National Clinical Trials Network Lead Academic Participating Site (NCTN LAPS-UG1). We view this opportunity as an important component of a large cancer research effort at our institution. We remain committed to the concept that multi-institutional collaboration is essential to the advancement of cancer treatment. Our goal as a LAPS site is to make significant scientific, leadership, administrative and patient data contributions to the NCTN effort to study and improve cancer therapy. The NCTN process involves the development and conduct of purposeful clinical trials, adoption of uniform toxicity and response criteria, collection of patient data, and results reporting. NCTN Group research is the only setting in which sophisticated concepts of combined modality and interdisciplinary therapy as well as adjuvant therapies can be properly evaluated. NCTN clinical research has also provided an improved understanding of the important relationships between prognostic factors, therapy and patient outcomes that could not have been obtained otherwise.